Product Description

Interleukin-8 (IL-8), also known as CXCL8, is a CXC family chemokine mainly produced by macrophages, monocytes, fibroblasts, and endothelial cells, playing central roles in inflammatory responses and immune cell recruitment. IL-8 functions primarily by binding to two G protein-coupled receptors, CXCR1 and CXCR2, thereby activating downstream signaling pathways including phospholipase C (PLC), MAPK, and PI3K-Akt, which induce cytoskeletal rearrangement, integrin activation, and chemotactic movement. The most classic function of IL-8 is the chemotaxis of neutrophils from the bloodstream to sites of inflammation; it also promotes the chemotaxis of other immune cells such as T cells and monocytes. For example, during acute infection, IL-8 is rapidly released, mediating the directed migration and activation of neutrophils to help clear pathogens, whereas persistent expression of IL-8 in chronic inflammation is associated with tissue damage and disease progression. In addition, IL-8 is involved in angiogenesis, tumor proliferation, and metastasis. Dysregulation of IL-8 is frequently observed in various disease states, such as chronic obstructive pulmonary disease (COPD), psoriasis, rheumatoid arthritis, and multiple cancers (e.g., breast cancer, colorectal cancer, melanoma), where it promotes tumor angiogenesis, invasion, and metastasis. Consequently, drugs targeting IL-8 or its receptors CXCR1/CXCR2 (e.g., the small-molecule CXCR2 inhibitors reparixin and navarixin) are under clinical development for the treatment of inflammatory diseases and cancers, underscoring the critical role of IL-8 in normal immune surveillance, inflammatory pathology, and tumor microenvironment regulation.

Screeningbio’s TR-FRET Human IL8 Detection Kit can be used to measure the levels of Human IL8 protein in supernatants. This kit is a sandwich immunoassay developed using TR-FRET technology, characterized by simplicity, rapidity, high specificity, high sensitivity, and good reproducibility.

The basic principle of this method is as follows: a pair of specific antibodies are separately conjugated to TR-FRET Solar Eu*1 (donor) and TR-FRET LA*2 (acceptor). When both antibodies bind to distinct epitopes of the Human IL8 protein, the TR-FRET donor and acceptor are brought into close proximity. Upon excitation by an external light source, fluorescence resonance energy transfer occurs between the donor and acceptor. The level of Human IL8 protein can then be determined by measuring the signal intensity at a specific wavelength (665 nm).